If you're wanting to add some ASX 200 shares to your portfolio, then you may want to check out the two listed below.
Here's why these ASX 200 shares come highly rated:
Image source: Getty Images
Goodman Group (ASX: GMG)
The first ASX 200 share to look at is Goodman Group. It is an integrated commercial and industrial property group which has generated consistently strong returns for investors over the last decade.
This has been underpinned by the diversity of Goodman's portfolio and its exposure to quick growing markets such as ecommerce.
Pleasingly, the ecommerce market has resulted in strong demand from blue chip customers such as Amazon, Showpo, and Walmart. And given how the shift to online shopping is only really getting started, these properties look set to be in strong demand for a long time to come.
One broker that is very positive on Goodman is Goldman Sachs. It has a buy rating and $25.40 price target on its shares.
ResMed Inc. (ASX: RMD)
Another ASX 200 share that has been rated as a buy is ResMed. It is a medical device company aiming to change lives by developing, manufacturing, and distributing innovative medical devices and cloud-based software solutions. These solutions help to better diagnose, treat, and manage sleep-disordered breathing, chronic obstructive pulmonary disease (COPD), and other key chronic diseases.
Demand has been strong for its innovative products in recent years, leading to stellar sales and earnings growth.
The good news is that ResMed appears well-placed to continue this positive form in the future. This is thanks to its world-class products, the massive number of undiagnosed sleep apnoea sufferers globally, and its rapidly growing digital health ecosystem.
Credit Suisse is positive on the company and has an outperform rating and $40.00 price target on its shares.
